Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood–Brain Barrier Both in Vitro and in Vivo by Aparicio-Blanco, Juan et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Cannabidiol Enhances the Passage of Lipid
Nanocapsules across the Blood–Brain Barrier Both in
Vitro and in Vivo
Journal Item
How to cite:
Aparicio-Blanco, Juan; Romero, Ignacio A.; Male, David K.; Slowing, Karia; Garcia-Garcia, Luis and Torres-
Suarez, Ana (2019). Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood–Brain Barrier Both
in Vitro and in Vivo. Molecular Pharmaceutics, 16(5) pp. 1999–2010.
For guidance on citations see FAQs.
c© 2019 American Chemical Society
Version: Accepted Manuscript
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1021/acs.molpharmaceut.8b01344
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
1 
 
Cannabidiol enhances the passage of lipid nanocapsules across the blood-brain 
barrier both in vitro and in vivo 
Juan Aparicio-Blanco a,b, Ignacio A. Romero b, David K. Male b, Karla Slowing c, Luis 
García c, Ana I. Torres-Suárez a, d,* 
a Department of Pharmaceutics and Food Technology, Complutense University, Madrid, 
Spain 
b School of Life, Health and Chemical Sciences, Faculty of Science, The Open University, 
Milton Keynes, United Kingdom 
c Department of Pharmacology, Pharmacognosy and Botany, Complutense University, 
Madrid, Spain 
d University Institute of Industrial Pharmacy, Complutense University, Madrid, Spain 
*Corresponding author: Prof. Ana I. Torres-Suárez 
Department of Pharmaceutics and Food Technology, Complutense University, 28040, 
Madrid, Spain  
Telephone: +34 91 394 1735; e-mail: galaaaa@ucm.es 
2 
 
Abstract 
Diseases affecting the central nervous system (CNS) should be regarded as a 
major health challenge due to the current lack of effective treatments given the hindrance 
to brain drug delivery imposed by the blood-brain barrier (BBB). Since efficient brain drug 
delivery should not solely rely on passive targeting, active targeting of nanomedicines 
into the CNS is being explored. 
The present study is devoted to the development of lipid nanocapsules (LNCs) 
decorated with non-psychotropic cannabinoids as pioneering non-immunogenic brain 
targeting molecules and to the evaluation of their brain targeting ability both in vitro and 
in vivo. Noticeably, both the permeability experiments across the hCMEC/D3 cell-based 
in vitro BBB model and the biodistribution experiments in mice consistently demonstrated 
that the highest brain targeting ability was achieved with the smallest-sized cannabinoid-
decorated LNCs. Importantly, the enhancement in brain targeting achieved with the 
conjugation of CBD to LNCs outperformed by 6-fold the enhancement observed for the 
G-Technology® (the main brain active strategy that has already entered clinical trials for 
the treatment of CNS diseases) As the transport efficiency across the BBB certainly 
determines the efficacy of the treatments for brain disorders, small cannabinoid-
decorated LNCs represent auspicious platforms for the design and development of novel 
therapies for CNS diseases. 
Keywords 
Cannabinoids, brain targeting, in vitro BBB model, permeability, nanomedicine 
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1. Introduction 
According to the Mental health: new understanding, new hope report by the World 
Health Organization, one in four people will be affected by mental or neurological 
disorders at some point in their lives, with approximately 450 million people worldwide 
currently suffering from such conditions. These prevalence data are expected to increase 
further due to the increase in life expectancy, emphasizing the need to face diseases 
affecting the central nervous system (CNS) as a major health challenge of the twenty-
first century 1. Unfortunately, the efficacy of the current standard of care for these 
diseases remains questionable in most cases, since the blood-brain barrier (BBB) truly 
hinders the distribution to the CNS of most drug substances administered systemically. 
In consequence, high doses are often required to achieve therapeutically meaningful 
levels in the CNS, and this causes severe toxicity to peripheral tissues. Therefore, there 
is a dire need for developing effective strategies of brain drug delivery that overcome 
biodistribution and pharmacokinetic limitations that account for treatment failure 2-4. 
The BBB consists of the endothelial cell monolayer of the brain capillaries closely 
associated with pericytes and astrocytes and is physiologically responsible for the 
maintenance of CNS homeostasis. The key features of the brain endothelium that 
account for the severe restriction to brain drug delivery are both the lack of fenestrations 
and the presence of tight intercellular junctions 5. Some of the described delivery 
strategies to circumvent the BBB such as the direct intracerebral administration 6 and the 
artificial disruption of the tight junctions by chemical or physical stimuli 7 involve high risk 
of neurological damage. Hence, every effort is currently being devoted to achieving 
efficient transport across the brain endothelium with targeted drug carriers following 
minimally-invasive intravenous injection. 
In this regard, the use of nanocarriers arises as an alternative to enhance the 
passage across the BBB 8. Noticeably, given their low toxicity, biocompatibility and 
biodegradability, the clinical trials launched heretofore for the treatment of brain 
conditions with nanomedicines mostly evaluate lipid-based nanocarriers 9. Since one 
major feature that certainly influences the in vivo performance of nanomedicines is 
particle size, a size-controlled extravasation at the target site based on 
pathophysiological features has traditionally been sought. Nonetheless, although the 
paracellular permeability of the brain endothelium is altered in most CNS diseases, the 
BBB dysfunction is typically only substantial in advanced stages of disease and in the 
most affected sites 10, 11. Therefore, efficient brain targeting of nanomedicines should not 
solely rely on passive targeting. To remedy this shortcoming, brain active targeting is 
being explored with the purpose of boosting transcellularly the delivery efficiency across 
the BBB 12. 
Brain active targeting is based on the modification of nanocarriers with moieties 
capable of triggering receptor-mediated transcytosis into the CNS through specific 
binding with endogenous transporters overexpressed on the brain endothelium. 
Remarkably, the transcytotic mechanisms that mediate the internalization of 
nanocarriers often follow a size-dependent pattern within the range 10-100 nm. In these 
cases, a fine control on particle size will certainly improve their potential therapeutic 
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outcome. Various receptors highly expressed on the cerebral endothelial cells (such as 
transferrin receptor 13, 14, nicotinic acetylcholine receptor 15, 16, low-density lipoprotein 
receptor 17, 18 and glucose transporter 19, 20) have been utilized to develop brain active 
targeting strategies. However, the translational impact of brain active targeting in clinical 
trials remains modest, as only three out of the eight liposomes that have made their way 
to clinical trials for distinct brain conditions following intravenous administration are 
actively-targeted (ClinicalTrials.gov identifiers: NCT01386580, NCT02048358 and 
NCT02340156). This is greatly due to the flaws that currently available targeting moieties 
have: on the one hand, the use of physiological ligands as targeting moieties can develop 
competitive phenomena with their endogenous counterparts and consequently alter 
brain homeostasis; whereas on the other hand, the use of targeting peptides must ensure 
non-immunogenicity 12. Hence, novel brain targeting moieties are strongly needed. 
Since any ligand for which a receptor exists on the cerebral endothelial cells may 
be potentially used for brain targeting, research on innovative exogenous non-
immunogenic ligands are likely to thrive in the near future. In this regard, we 
hypothesized that cannabinoids hold great promise for brain active targeting. In 
particular, cannabidiol (CBD), the main phytocannabinoid devoid of psychotropic effects 
with high BBB transcytosis efficacy, is the appropriate lead candidate to test the 
possibilities of this hypothesis. Effectively, this cannabinoid has been postulated to bind 
to various receptors located on the brain endothelium environment 21, namely the CB1-
receptor 22, the serotonin receptor 5-HT1A 23, the transient potential vanilloid receptor 
type-1 (TRPV-1) 24, the G protein-coupled receptor 55 (GPR55) 25, the adenosine A2A 
receptor 26 and the dopamine receptor D2 27. 
Therefore, we decorated lipid nanocapsules (LNCs) with CBD. After having 
screened the influence of critical parameters of these colloid systems as targeted 
prolonged release carriers against glioma cells 28, we pioneeringly evaluated herein their 
brain targeting ability as a first-in-a-new class of exogenous non-immunogenic-targeted 
carriers for brain active targeting to achieve higher translational impact. The brain 
targeting ability was evaluated both in vitro and in vivo. Cell viability, uptake and 
permeability experiments were conducted on the human brain endothelial cell line 
hCMEC/D3. The in vitro permeability coefficients across the hCMEC/D3 monolayer were 
validated with in vivo data from biodistribution studies in mice. Both the role played by 
particle size and functionalization with CBD in the extent of passage across the BBB was 
evaluated. 
2. Experimental section 
2.1. Materials 
Labrafac® lipophile WL 1349 (caprylic-capric acid triglycerides) was kindly 
supplied by Gattefossé. Kolliphor® HS15 (C18E15 polyethylene glycol (15) 12-
hydroxystearate) was a gift from BASF. Lipoid® S75 (soybean lecithin with 70% of 
phosphatidylcholine) was supplied by Lipoid-Gmbh. NaCl was purchased from Panreac. 
De-ionized water was obtained from a MilliQ® Purification System. The fluorescent dyes 
3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine 4-chlorobenzenesulfonate salt (DiD) were purchased 
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from Invitrogen Molecular Probes. Cannabidiol (CBD) was provided by THC-Pharma. 
Endothelial Cell Basal Medium-2 (EBM-2) and culture supplements were purchased from 
Lonza. Dulbecco’s Modified Eagle Medium (DMEM) devoid of phenol red was provided 
by Gibco. Tetramethyl-rhodamine-isothiocyanate–dextran (TRITC-dextran, MW 150 
kDa), type I collagen from calf skin, fibronectin from bovine plasma, Hank’s Balanced 
Salt Solution (HBSS), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT), dimethyl-sulfoxide (DMSO) and sterile Nunc Lab-Tek® chamber slides (8 wells, 
Permanox® slide, 0.8 cm2/well) were purchased from Sigma-Aldrich. Vectashield® 
mounting medium with DAPI (H-1200) was provided by Vector Laboratories. Sterile 
Millicell® Hanging Cell Culture Inserts were supplied by Millipore (12-well culture plates; 
membrane: polyethylene terephthalate membrane; pore size: 1.0 μm; membrane surface 
area: 1.1 cm2). 
2.2. Cell line 
The human brain endothelial hCMEC/D3 cells were seeded in collagen-coated 
flasks and cultured in EBM-2 medium supplemented with 2.5% foetal bovine serum 
(FBS), 0.025% (v/v) rhEGF, 0.025% (v/v) VEGF 0.025% IGF, 0.1% (v/v) rhFGF, 0.1% 
(v/v) gentamycin, 0.1% (v/v) ascorbic acid and 0.04% (v/v) hydrocortisone at 37ºC in 
95% air and 5% CO2. For all experiments, cells between passage 25 and 30 were used. 
2.3. Animals 
Male ICR mice, aging 4-5 weeks and weighting 29 ± 3 g, were purchased from 
Envigo. The mice were housed in ventilated cages with free water and food in a 12h 
dark/light cycle. Animals were acclimated for one week before the experiment. All in vivo 
experiments were approved by the Ethics Committee of the Community of Madrid (Ref. 
PROEX 111/14) and conducted according to Spanish and European guidelines 
(Directive 86/609/EEC). 
2.4. Preparation and characterization of lipid nanocapsules (LNCs) 
2.4.1. Blank LNCs (F1, F2) 
LNCs were prepared by the phase inversion temperature (PIT) method. This low 
energy method has recently been fully characterized in 29. Succinctly, Labrafac® lipophile 
WL 1349, Kolliphor® HS15, Lipoid® S75, NaCl and water were mixed under magnetic 
stirring and progressively heated over the phase inversion temperature of the system. 
Subsequently, the mixture was gradually cooled down until the phase inversion 
temperature was reached (namely, 70 ºC). Then, a sudden quench with cold water (5 
mL) was performed to obtain the final suspension of LNCs. By varying the relative 
proportions of the excipients as shown in Table 1, blank LNCs in different sizes were 
prepared. 
2.4.2. Fluorescently-labeled LNCs (F3, F4, F5, F6) 
The fluorescent dyes DiO and DiD were encapsulated in LNCs for particle 
tracking purposes in in vitro and in vivo experiments, respectively. To prepare the dye-
loaded LNCs, the fluorescent dye was firstly dissolved in the oily phase that constitutes 
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the core of the LNCs at a weight ratio of 15 mg of dye/g of Labrafac® lipophile WL1349. 
Then, the remaining excipients were added and progressively heated and cooled down 
around the phase inversion temperature as indicated in 2.4.1. 
2.4.3. LNCs decorated with cannabidiol (CBD) (F7, F8, F9, F10) 
Pre-formed fluorescently-labeled LNCs were incubated with a CBD solution (15 
mg/mL) in a 3:1 (v/v) ratio. The mixture was gently stirred overnight (250 rpm) until 
complete solvent evaporation following a previous protocol for the adsorption of targeting 
moieties on the surface of LNCs with minor modifications 30. The contribution of the 
solvent itself to the size distribution of LNCs was ruled out by incubating LNCs with pure 
solvent up to above the 3:1 (v/v) ratio. 
The detailed excipients weight for each formulation of LNCs is shown in Table 1. 
The mean volume diameter and polydispersity index (PdI) of each formulation were 
measured by dynamic light scattering (DLS) using a Microtrac® Zetatrac™ Analyzer 
(Microtrac Inc., USA). Measurements were done in triplicate. 
2.5. In vitro cytotoxicity 
LNCs were assessed for cytotoxicity against hCMEC/D3 cells using an MTT 
assay. Briefly, hCMEC/D3 cells were seeded into collagen-coated 96-well plates at a 
density of 2 x 104 cells/well. After cells had been confluent for 48 hours, they were treated 
with suspensions of LNCs (200 µL) for 1, 4 and 24 hours in three different experiments. 
Then, the medium was removed and 60 µL of MTT solution (1 mg/mL) in complete EBM-
2 were added to each well and incubated for 4 hours. Afterwards, the media containing 
MTT was removed and 100 µL of DMSO was added to each well. The plates were 
agitated for 10 minutes and the absorbance was measured at 570 nm using a microplate 
reader (FLUOstar Omega, BMG Labtech). Experiments were performed in triplicate at 
each time-point. hCMEC/D3 cells without treatment served as control. Cell viability of 
each group was expressed as a percentage relative to that of control. 
2.6. In vitro cellular uptake 
2.6.1 Uptake experiments evaluated by flow cytometry 
To quantitatively evaluate the BBB targeting ability of LNCs in vitro, hCMEC/D3 
cells were seeded into collagen-coated 6-well plates at a density of 3 x 105 cells/well. 
After cells had been confluent for 48 hours, the culture medium was replaced by DiO-
labeled LNCs (F3, F4, F7 and F8 at an equivalent dye concentration of 1.65 µg DiO/mL 
of suspension) suspended in complete EBM-2 (2 mL) wherewith cells were incubated for 
4 and 24 hours in two different experiments. Then, cells were rinsed with HBSS, 
trypsinized and finally resuspended in 0.3 mL HBSS. The fluorescence intensity of cells 
treated with fluorescent-LNCs was analyzed with a flow cytometer (FACScalibur, BD 
Biosciences; λ excitation: 488 nm; λ emission: 530 nm). Experiments were performed in 
triplicate at each time-point. hCMEC/D3 cells treated with blank LNCs served as control. 
Cellular uptake of each group was expressed as fold-increase in fluorescence mean 
relative to that of control after correction for the different amount of dye per individual 
LNC in each formulation. 
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2.6.2. Uptake experiments evaluated by laser scanning confocal microscopy 
To qualitatively illustrate the BBB targeting ability of LNCs in vitro, hCMEC/D3 
cells were seeded into collagen- and fibronectin-coated chamber slides at a density of 3 
x 104 cells/well. After cells had been confluent for 48 hours, the culture medium was 
replaced by undecorated or CBD-functionalized DiO-labeled LNCs at an equivalent dye 
concentration of 1.65 µg DiO/mL suspended in complete EBM-2 (0.3 mL) wherewith cells 
were incubated for 24 hours. Then, cells were rinsed with HBSS and mounted with 
Vectashield® with DAPI mounting medium. The cells were then observed with a laser 
scanning confocal microscope (Leica SP5, 405 nm for DAPI, 488 nm for DiO) using 
LEICA LAS AF software. hCMEC/D3 cells treated with blank LNCs served as control. 3D 
imaging reconstruction was performed by means of IMARIS software. 
2.7. Monolayer integrity in the presence of lipid nanocapsules 
An in vitro BBB model with the human cerebral endothelial cell line hCMEC/D3 
was established. Succinctly, hCMEC/D3 cells were seeded into collagen- and 
fibronectin-coated 12-well hanging cell culture inserts at confluence and incubated for 72 
hours in complete EBM-2. The monolayer integrity was assessed by determining the 
permeability coefficient across the hCMEC/D3 monolayer of the hydrophilic tracer 
TRITC-dextran both in the presence and the absence of LNCs. Briefly, 400 μL of a 
TRITC-dextran solution (2 mg/mL) in DMEM without phenol red supplemented with 0.1% 
(v/v) FBS were added in the apical chamber of both cell-seeded and non-seeded inserts, 
whereas 1.2 mL of fresh DMEM without phenol red supplemented with 0.1% (v/v) FBS 
were added in the receptor chamber. At 2, 4, 6, 8, 12 and 24 hours, 200 μL from the 
basolateral compartment were sampled and replaced with fresh medium. At 24 hours, 
the apical compartment was likewise sampled (100 μL). The concentration of TRITC-
dextran was determined using a microplate reader (FLUOstar Omega, BMG Labtech, 
excitation wavelength: 544 nm, emission wavelength: 590 nm). The concentrations at 
the different time points were used to define a linear region within which the permeability 
coefficients can be calculated 31. The apparent permeability coefficients were calculated 
using Equation 1: 
𝑃𝑎𝑝𝑝(
𝑐𝑚
𝑠⁄ ) =  −
𝑉𝐷∗𝑉𝐴
𝐴∗𝑡(𝑉𝐷+𝑉𝐴)
ln (1 −
(𝑉𝐷+𝑉𝐴)
𝑉𝐷
𝐶𝐴(𝑡)
𝐶𝐷(0)
) (Equation 1) 
where CD(0) is the TRITC-dextran concentration placed in the donor 
compartment at the beginning of the experiment; CD(t) and CA (t) are the sample 
concentrations after the incubation time has elapsed in the donor and acceptor 
compartment, respectively; t is the time; A is the surface area of the filter insert, and VD 
and VA are the volume of buffer solution in the donor and acceptor compartment, 
respectively. 
To calculate the effective TRITC-dextran permeability (Peff), the contribution of 
the insert support to the overall resistance was included as detailed in Equation 2: 
1
𝐴∗𝑃𝑒𝑓𝑓
ℎ𝐶𝑀𝐸𝐶/𝐷3 𝑚𝑜𝑛𝑜𝑙𝑎𝑦𝑒𝑟 =
1
𝐴∗𝑃𝑎𝑝𝑝
𝑐𝑒𝑙𝑙+𝑓𝑖𝑙𝑡𝑒𝑟 −
1
𝐴∗𝑃𝑎𝑝𝑝
𝑓𝑖𝑙𝑡𝑒𝑟 (Equation 2) 
where A is the surface area of the filter insert, Peffmonolayer stands for the effective 
permeability solely due to the hCMEC/D3 monolayer, Pappcell+filter is the apparent 
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permeability calculated for the cell-seeded inserts and Pappfilter is the apparent 
permeability calculated for the filters with no cells. Experiments were done in triplicate. 
2.8. Transport of LNCs across the hCMEC/D3 monolayer in vitro 
After having established the in vitro BBB model with hCMEC/D3 cell line as 
described in 2.7, 400 μL of a suspension of DiO fluorescently-labeled LNCs (F3, F4, F7 
and F8 at an equivalent dye concentration of 1.65 µg DiO/mL of suspension) in DMEM 
without phenol red supplemented with 0.1% (v/v) FBS were added in the apical chamber 
of both cell-seeded and non-seeded inserts, whereas 1.2 mL of fresh DMEM without 
phenol red supplemented with 0.1% (v/v) FBS were added in the receptor chamber. At 
2, 4, 6, 8, 12 and 24 hours, 200 μL from the basolateral compartment were sampled and 
replaced with fresh medium. At 24 hours, the apical compartment was also sampled (100 
μL). The concentration of DiO was determined using a microplate reader (FLUOstar 
Omega, BMG Labtech, excitation wavelength: 485 nm, emission wavelength: 520 nm). 
These concentrations were used to calculate the effective permeability coefficients (Peff) 
as described in 2.7. Only in those cases wherein less than 90% of the DiO dose was 
recovered between both apical and basolateral chambers, was Equation 1 replaced by 
Equation 3 to take the retention factor (R) into account:  
𝑃𝑎𝑝𝑝(
𝑐𝑚
𝑠⁄ ) =  −
𝑉𝐷∗𝑉𝐴
𝐴∗𝑡(𝑉𝐷+𝑉𝐴)
ln (1 −
(𝑉𝐷+𝑉𝐴)
𝑉𝐷
𝐶𝐴(𝑡)
(1−𝑅)∗𝐶𝐷(0)
) Equation 3 
2.9. Biodistribution of LNCs in healthy mice 
The tissue biodistribution of LNCs was investigated in healthy mice. The mice 
(n=4-5 per group) were injected via the tail vein with 150 μL of different DiD-fluorescently-
labeled LNCs (F5, F6, F9, F10). Ninety minutes (for all formulations) and four hours (for 
F5 and F9) after administration, mice were sacrificed, and the brain, liver, spleen, 
kidneys, lungs, heart and blood were collected and homogenized in ethanol for dye 
extraction. The concentration of DiD was measured using a microplate reader (Varioskan 
Flash, Thermo Scientific, excitation wavelength: 644 nm, emission wavelength: 665 nm). 
Results were expressed as percentage of the injected dose per organ. 
2.10. Statistical analysis 
All experiments were done at least in triplicate and all data are expressed as 
mean ± SD. Unpaired Student’s t test was used for two-group analysis. Statistical 
significance was fixed as *: p<0.05, **: p<0.01, ***: p<0.001. All the data were analyzed 
using the GraphPad Prism 7 software. 
3. Results 
3.1. Preparation and characterization of lipid nanocapsules 
Ten different formulations of LNCs were prepared by the PIT method by varying 
their relative proportions of excipients as detailed in Table 1. Likewise, the size 
distribution of all LNC formulations is included in Table 1, both in terms of average 
volume diameter and polydispersity index. In all cases, monodisperse nanocapsules 
were obtained within the size range of 20-60 nm. In particular, we obtained highly 
monodisperse blank LNCs of 20 nm (F1) and 40 nm (F2). Noticeably, the inclusion of 
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fluorescent dyes did not significantly vary the size distribution of their blank counterparts: 
after loading F1 and F2 with fluorescent dyes, we obtained analogous 20 nm- (F3 and 
F5 for DiO and DiD, respectively) and 40 nm- (F4 and F6 for DiO and DiD, respectively) 
sized LNCs. Conversely, as thoroughly detailed in a previous study28, the 
functionalization of LNCs with CBD significantly altered their average volume diameter: 
the decoration of dye-loaded LNCs with CBD increased the particle size to 40 nm (F7 
and F9) and 55 nm (F8 and F10), respectively. This increase in particle size was solely 
due to the presence of the cannabinoid, since the contribution of the solvent was ruled 
out following incubation of LNCs with the pure solvent at the same ratio (Figure S1). 
Hence, the role played by particle size in the BBB targeting properties will be first 
assessed separately in non-modified LNCs and in CBD-decorated LNCs. As the increase 
of particle size due to functionalization within this interval (20-60 nm) represents a higher 
percentage increase than in the most widely explored 100-nm range, should particle size 
play a statistically significant role in the BBB targeting properties, the influence of CBD-
decoration will be then evaluated for equally-sized LNCs to maintain the size variable 
constant. 
Moreover, as thoroughly discussed in a previous article28, slightly negative zeta 
potential were obtained for all formulations, although the functionalization strategy with 
CBD considerably smoothed the zeta potential profiles in comparison to those of 
unfunctionalized LNCs (namely, a 3.5-3.8-fold reduction in zeta potential profile width), 
in agreement with the hypothesized superficial location of CBD. 
Table 1: Detailed excipients weight and size distribution properties for each 
formulation of LNC in final suspension. 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Excipient weight (mg) 
Kolliphor® 
HS15  
1934 846 1934 846 1934 846 645 282 645 282 
Lipoid® 
S75 
75 75 75 75 75 75 25 25 25 25 
NaCl 89 89 89 89 89 89 30 30 30 30 
Labrafac® 
lipophile 
WL 1349 
846 1028 846 1028 846 1028 282 343 282 343 
Water 6056 6962 6056 6962 6056 6962 2018 2320 2018 2320 
DiO - - 12 15 - - 4 5 - - 
DiD - - - - 12 15 - - 4 5 
CBD - - - - - - 15 15 15 15 
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Size distribution 
Average 
volume 
diameter 
(nm) 
21.29 
± 
0.90 
42.50 
± 
1.08 
22.78 
± 
0.49 
43.85 
± 
0.78 
21.11 
± 
0.25 
40.43 
± 
0.65 
43.00 
± 
2.97 
62.75 
± 
0.49 
38.6 
± 
0.96 
52.40 
± 
0.75 
Polydisper
sity index 
(PdI) 
0.040 
± 
0.008 
0.052 
± 
0.004 
0.068 
± 
0.016 
0.044 
± 
0.013 
0.037 
± 
0.004 
0.046 
± 
0.03 
0.105 
± 
0.022 
0.083 
± 
0.001 
0.106 
± 
0.007 
0.064 
± 
0.001 
3.2. In vitro cytotoxicity 
To determine the suitability of LNCs for conducting the in vitro experiments with 
the hCMEC/D3 monolayer, an MTT assay was used. Consistently, hCMEC/D3 cells were 
incubated with F1 and F2-LNCs at an equivalent concentration of 110 μg of internal oily 
phase/mL of nanocapsule suspension to ultimately normalize the in vitro studies as a 
function of the different payloads (fluorescent dye). Figure 1 shows the cytotoxicity 
observed for 1, 4 and 24 hours. Remarkably, no toxicity was observed for none of the 
LNCs at any time point (p>0.05). Therefore, these formulations at this suitable non-toxic 
concentration (that corresponds to an equivalent concentration of 1.65 μg of DiO/mL for 
the fluorescently-labeled LNCs) were used hereafter for all subsequent in vitro 
experiments. 
 
Figure 1: In vitro cytotoxicity of LNCs against hCMEC/D3 cells at different time 
points: 20 nm- (F1) and 40 nm- (F2) sized LNCs in suspension at an equivalent DiO 
concentration of 1.65 μg DiO/mL (p>0.05). 
3.3. In vitro cellular uptake 
The BBB targeting ability of DiO-labeled LNCs (F3, F4, F7 and F8 at an 
equivalent dye concentration of 1.65 µg DiO/mL of suspension) was tested in vitro. The 
quantitative analysis by flow cytometry of the cellular uptake after 4 and 24 hours of 
incubation is shown in Figure 2. All formulations exhibited a time-dependent cellular 
uptake with higher fluorescence intensities after incubating hCMEC/D3 cells with LNCs 
for 24 hours (**: p<0.01). Likewise, a consistent comparison of the role played by particle 
size can be drawn for non-modified LNCs (F3 vs F4, Figure 2a) and for CBD-decorated 
LNCs (F7 vs F8, Figure 2b). In both cases the smaller the particle size, the higher their 
uptake by the human cerebral endothelial cells (***: p<0.001 and **: p<0.01 at 4 and 24 
hours, respectively). Given the influence of particle size in the cellular uptake, the 
influence of CBD-decoration was then evaluated from a comparison of equally-sized 
non-modified and CBD-decorated LNCs. Interestingly, the functionalization with CBD 
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also enhanced the in vitro BBB targeting properties of LNC (Figure 2c, ***:p<0.001 and 
*: p<0.05 at 4 and 24 hours, respectively). The trends in cellular uptake were steady 
throughout the period evaluated. 
 
Figure 2: Evaluation of the in vitro cellular uptake of LNCs by flow cytometry 
expressed as folds increase in mean fluorescence intensity versus control. (a) Evaluation 
of the role of particle size in the in vitro cellular uptake (non-modified LNCs) at 4 and 24 
hours (***: p<0.001 and **: p<0.01, respectively). (b) Evaluation of the role of particle 
size in the in vitro cellular uptake (CBD-decorated LNCs) at 4 and 24 hours (***: p<0.001 
and **: p<0.01, respectively). (c) Evaluation of the role of cannabinoids on the in vitro 
cellular uptake (equally-sized LNCs) at 4 and 24 hours (***: p<0.001 and *: p<0.05, 
respectively). 
The in vitro BBB targeting ability of LNCs was further evidenced qualitatively by 
laser scanning confocal microscopy. As shown in Figure 3, both undecorated and CBD-
functionalized LNCs were internalized by hCMEC/D3 in accordance with the data 
obtained by flow cytometry. The 3D video reconstruction performed by means of the 
IMARIS software with the Z-stack projections helped evidence that the fluorescent signal 
from LNCs localized in the intracellular compartment of the cerebral endothelial cells, 
preferentially in the perinuclear region (Supplementary material). 
Given the negligible basal fluorescence of the lipophilic carbocyanine dye in 
aqueous media as declared by supplier and the lack of release of indocarbocyanine dyes 
from LNCs even against lipophilic compartments32 and the lack of detectable transfer of 
indocarbocyanine fluorescent dyes from LNCs to cells33, the measured fluorescence is 
in all cases due to LNC-encapsulated DiO. 
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Figure 3: Evaluation of the in vitro cellular uptake of LNCs by confocal 
microscopy: DAPI (left), DiO (center), merged (right). (a) Blank LNCs (F2). (b) DiO-
labeled LNCs (F4). (c) CBD-decorated DiO-labeled LNCs (F8). Scale bar = 25 μm. 3D 
video reconstructions from the Z-stack projections are available as Supplementary 
material. 
3.4. Monolayer integrity of the in vitro BBB model in the presence of LNCs 
The in vitro BBB model with a monolayer of hCMEC/D3 cells was established. 
This method and the culture conditions had been previously optimized to achieve the 
highest transendothelial electrical resistance (TEER) value in monoculture 34. The effect 
of LNCs on the integrity of confluent cerebral endothelial cell monolayers was 
investigated by determining the permeability coefficient of fluorescent TRITC-dextran. 
The cellular model provided permeability coefficients for dextran in the order to those 
reported in the literature.35 Importantly, there were no statistically significant differences 
between the calculated permeability coefficients of TRITC-dextran in the presence and 
the absence of LNCs (1.67 ± 0.44 x 10-7 cm/s versus 1.77 ± 0.33 x 10-7 cm/s, p>0.05). 
This restriction to the paracellular route was maintained throughout the assay, confirming 
that the sample itself did not enhance the paracellular route. Consequently, it was 
concluded that, during the period evaluated, LNCs did not significantly alter the tightness 
of the hCMEC/D3 monolayer. These results ultimately enabled the paracellular 
contribution to the ensuing in vitro transport experiments of LNCs across the monolayer 
to be ruled out during at least 24 hours. 
3.5. Transport of LNCs across the hCMEC/D3 monolayer in vitro 
13 
 
The BBB transcytosis ability of DiO-labeled LNCs (F3, F4, F7 and F8 at an 
equivalent dye concentration of 1.65 µg DiO/mL of suspension) was quantitatively 
assessed in vitro by determining the permeability coefficient of LNCs across the 
hCMEC/D3 monolayer. In line with the results obtained for cellular uptake, a consistent 
comparison of the role played by particle size can be drawn for non-modified LNCs (F3 
vs F4, Figure 4a) and for CBD-decorated LNCs (F7 vs F8, Figure 4b). In both cases the 
smaller the particle size, the higher the permeability coefficient and the ensuing BBB 
transcytosis ability (6.54 ± 0.75 x 10-8 cm/s versus 2.66 ± 1.05 x 10-8 cm/s, **: p<0.01; 
and 1.15 ± 0.13 x 10-7 cm/s versus 4.63 ± 0.34 x 10-8 cm/s, ***: p<0.001, respectively). 
Given the influence of particle size in the permeability coefficient, the influence of CBD-
decoration was then evaluated from a comparison of the permeability coefficients of 
equally-sized non-modified and CBD-decorated LNCs. Noticeably, as expected from the 
cellular uptake results, the modification with CBD also enhanced the permeability 
coefficients of LNCs (Figure 4c, 2.66 ± 1.05 x 10-8 cm/s versus 1.15 ± 0.13 x 10-7 cm/s, 
***: p<0.001). 
As demonstrated in our previous study28, the slow CBD release from LNCs in cell 
culture (slower than the timeframes evaluated in the current study) serves to rule out the 
contribution of the effect of free CBD. 
 
Figure 4: Evaluation of the influence of different factors on the in vitro permeability 
of LNCs across the hCMEC/D3 monolayer. (a) Influence of particle size on permeability 
coefficients (non-modified LNCs) (**: p<0.01). (b) Influence of particle size on 
permeability coefficients (CBD-decorated LNCs) (***: p<0.001). (c) Influence of the 
modification with CBD on permeability coefficients (equally-sized LNCs) (***: p<0.001). 
3.6. Biodistribution of LNCs in healthy mice 
The BBB targeting properties of DiD-labeled LNCs (F5, F6, F9, F10) were 
assessed in vivo. We ruled out the possible toxicity of our formulations as, on the one 
hand, for biodistribution experiments in mice, we used the same doses previously 
reported in the literature as non-toxic for lipid nanocapsules administered intravenously 
36 and, on the other hand, cannabidiol has been reported to be tolerated at a dose up to 
120 mg/kg in mice (a much higher dose than that one used in the current study)37, 38. A 
proof-of-concept study confirmed that these doses were well tolerated by mice for any of 
the different tested evaluated in the current study. 
For in vivo experiments, we switched to the near-infrared dye DiD as it is excited 
and emits within the wavelength window of 640−800 nm (namely, the wavelength range 
with the lowest absorption in tissue). We determined the percentage of the injected dose 
of the different DiD-labeled LNCs located in each major organ (namely, blood, brain, 
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lungs, kidneys, heart, spleen and liver) following intravenous injection. The blood was 
estimated to represent 6% of the mice weight to calculate the total percentage of the 
dose existing in this compartment. The percentages of injected dose in all organs but for 
the brain are shown in Figure 5. Particle size certainly influences the in vivo 
biodistribution of LNCs: smaller nanocapsules achieved significantly higher plasma 
levels; whereas bigger LNCs were recognized to a higher extent by the 
reticuloendothelial organs (liver and spleen). These size-dependent results were 
consistently obtained both with non-modified LNCs (Figure 5a) and with CBD-decorated 
LNCs (Figure 5b). Alternatively, for equally-sized LNCs, the presence of CBD helped 
extend their plasma levels and concomitantly reduced the extent of removal by the liver 
(Figure 5c). 
 
Figure 5: In vivo biodistribution of DiD-labeled LNCs in healthy mice 90 minutes 
after their intravenous injection (expressed as percentage of the injected dose per organ; 
namely, blood, lungs, kidneys, heart, spleen and liver). (a) Influence of particle size on 
biodistribution (non-modified LNCs). (b) Influence of particle size on biodistribution 
(CBD-decorated LNCs). (c) Influence of the modification with CBD on biodistribution 
(equally-sized LNCs). 
The percentage of the injected dose distributed into the brain in each case is 
shown in Figure 6. In accordance with the in vitro results, both particle size and 
decoration with CBD played a pivotal role in in vivo brain targeting. Smaller LNCs showed 
significantly higher brain targeting properties. This trend was steadily observed both for 
non-modified LNCs (Figure 6a, 0.185 ± 0.022 % injected dose/brain versus 0.115 ± 0.036 
% injected dose/brain, *: p<0.05) and for CBD-decorated LNCs (Figure 6b, 0.290 ± 0.088 
% injected dose/brain versus 0.116 ± 0.008 % injected dose/brain, **: p<0.01). As particle 
size influenced the extent of brain distribution, the contribution of CBD-decoration was 
then assessed from a comparison of equally-sized non-modified and CBD-decorated 
LNCs. Remarkably, the modification of LNCs with CBD significantly contributed to 
enhance the BBB targeting properties of LNCs in vivo (Figure 6c, 0.115 ± 0.036 % 
injected dose/brain versus 0.290 ± 0.088 % injected dose/brain, *: p<0.05). 
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Figure 6: In vivo biodistribution of DiD-labeled LNCs in the brain of healthy mice 
90 minutes after their intravenous injection (expressed as percentage of the injected 
dose). (a) Influence of particle size on biodistribution (non-modified LNCs) (*: p<0.05). 
(b) Influence of particle size on biodistribution (CBD-decorated LNCs) (**: p<0.01). (c) 
Influence of the modification with CBD on biodistribution (equally-sized LNCs) (*: 
p<0.05). 
The biodistribution of LNCs on a longer term (4 hours after administration) was 
assessed for those formulations with the highest levels in plasma 90 minutes after 
administration (namely, F5 and F9). Figures 7 and 8 represent the time-course of the 
percentage of the injected dose in the major organs and in the brain, respectively. In 
comparison with their biodistribution at an earlier time point, the percentage of the 
injected dose in blood and brain decreased with time, whereas the levels in the 
reticuloendothelial organs progressively augmented. Similar trends were observed for 
F5 (Figures 7a and 8a) and for F9 (Figures 7b and 8b). 
 
Figure 7: In vivo biodistribution of DiD-labeled LNCs in healthy mice (expressed 
as percentage of the injected dose per organ; namely, blood, lungs, kidneys, heart, 
spleen and liver). Time-course biodistribution of (a) DiD-labeled LNCs (F5) and (b) CBD-
decorated DiD-labeled LNCs (F9). 
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Figure 8: In vivo biodistribution of DiD-labeled LNCs in the brain of healthy mice 
(expressed as percentage of the injected dose). Time-course biodistribution of (a) DiD-
labeled LNCs (F5) and (b) CBD-decorated DiD-labeled LNCs (F9). 
4. Discussion 
Brain diseases represent a major health challenge as brain drug delivery is 
hampered by the blood-brain barrier (BBB) 39. To augment the extent of brain drug 
delivery, intravenously-administered nanomedicines have already reached clinical trials 
for the treatment of different central nervous system (CNS) diseases (with a focus on 
brain tumors, but also including neurodegenerative diseases such as multiple sclerosis). 
Most of these clinical trials evaluate passively-targeted liposomes (ClinicalTrials.gov 
Identifiers: NCT00734682, NCT02861222, NCT00019630, NCT00944801, 
NCT01222780). However, given that the hypothesized BBB disruption in most CNS 
diseases only occurs substantially in advances stages and in the most damaged areas, 
passive targeting of nanomedicines should be supplemented with brain active targeting 
40. Importantly, for brain active targeting to achieve high translational impact, some 
criteria in the selection of targeting moieties must be met to prevent competitive 
phenomena with endogenous substrates and ensure non-immunogenicity 12. As a result, 
research on novel exogenous non-immunogenic ligands has become a research 
hotspot. 
In the present study we have prepared cannabidiol (CBD)-decorated lipid 
nanocapsules (LNCs) as innovative candidates to achieve brain targeting. Their brain 
targeting ability was evaluated both in vitro and in vivo. LNCs were chosen according 
both to their high drug loading potential within their oily core (unlike liposomes) and to 
their high kinetic stability provided by their solid surfactant shell. These carriers were 
prepared by the energetically-efficient phase inversion temperature (PIT) method. To 
evaluate the influence of particle size on the transcytosis mechanisms that mediate brain 
targeting, monodisperse LNCs in different sizes were prepared by varying the relative 
proportions of their excipients (Table 1). Alternatively, we hypothesized that given the 
plethora of receptors of the CNS to which cannabinoids have been reported to bind, 
cannabinoids hold great promise to enhance the brain targeting properties of 
nanocarriers. In particular, cannabidiol (CBD), the main cannabinoid devoid of 
psychotropic effects, seems the appropriate lead candidate to test the possibilities of this 
hypothesis 21. Hence, preformed LNCs were decorated with CBD to evaluate its role as 
brain targeting molecule. 
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The different LNCs were firstly evaluated in vitro with cell viability, uptake and 
permeability experiments conducted on the human brain endothelial cell line hCMEC/D3. 
This cell line was used as the in vitro BBB model given both their human origin and their 
better barrier properties in comparison with other commonly used cell lines 41. Through 
cell viability experiments on hCMEC/D3 cells. we determined non-toxic concentrations 
to perform both the uptake and permeability experiments at equivalent concentrations of 
the dye-labeled LNCs. 
The BBB targeting efficiency of dye-labeled LNCs was measured by their cellular 
uptake through flow cytometry. The internalization of LNCs by hCMEC/D3 followed a 
time-dependent pattern. Results consistently demonstrated a significantly higher BBB-
targeting effect for smaller LNCs (for both unmodified-LNCs and CBD-decorated LNCs) 
and for CBD-decorated LNCs (for equally-sized LNCs). The images taken by confocal 
microscopy further evidenced qualitatively the efficient internalization of LNCs. A 3D 
video reconstruction of the Z-stacks of these images seems to support a perinuclear 
localization of the LNCs within the hCMEC/D3 cells. 
The BBB transcytosis efficiency of dye-labeled LNCs was measured through 
permeability experiments across the in vitro BBB model. The integrity of the BBB model 
throughout the 24 hours that lasted the permeability experiments was previously 
demonstrated with TRITC-dextran as hydrophilic tracer: a comparison of the permeability 
coefficients of TRITC-dextran across the endothelial cell monolayer in vitro was not 
altered by the presence of LNCs (p>0.05). As a result, the in vitro BBB model was 
suitable for evaluating the transport ability of the different LNCs. We calculated herein 
the permeability coefficient as a robust parameter that enables the comparison of the 
different transport efficiencies. Importantly, permeability coefficient remains constant 
throughout the experiment, which is not the case for the transport ratio expressed as 
percentage of passage across the endothelial monolayer. Although this ratio is being 
broadly utilized to express transport efficiencies 13, 15, 16, 19, 42-45, it varies with the different 
time points and does not take into account important experimental parameters such as 
the insert surface area or the volumes of the acceptor and the donor chambers to 
normalize the data (which is precisely one of the main advantages of in vitro studies in 
comparison with the higher unquantifiable variability of in vivo experiments). For this 
reason, the efficiency of different brain active targeting strategies cannot be readily 
compared with transport ratios calculated as percentage. In order to attempt a 
comparison between various BBB-targeting peptides, Chen et al recently evaluated all 
these ligands in the same nanocarrier 17. Nevertheless, this strategy will no longer be 
plausible with the widening of the brain targeting armamentarium. Noticeably, the cellular 
uptake results were consistent with the permeability experiments: the permeability 
coefficients across the endothelial monolayer were significantly higher for smaller LNCs 
(for both unmodified-LNCs and CBD-decorated LNCs) and for CBD-decorated LNCs (for 
equally-sized LNCs). Taken together, the in vitro results highlighted that CBD 
modification on LNCs plays a major role in the transport enhancement across the BBB 
model and so does a reduction in particle size (within the tested size-range of 20-60 nm). 
The in vitro BBB-targeting and penetrating properties across the hCMEC/D3 
monolayers were validated with biodistribution studies in mice following intravenous 
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administration of dye-loaded LNCs. Although brain targeting efficiency has often been 
evaluated in pathophysiological models, given that BBB dysfunction only occurs in the 
most damaged brain regions, we aimed at evidencing targeting properties at earlier 
stages of the CNS diseases with biodistribution studies in healthy mice. Accordingly, we 
were forced to test smaller-sized nanocapsules (20-55 nm) than the 100 nm-sized (or 
even above) carriers that have been developed for their evaluation in rodent models of 
CNS diseases 13, 15, 17, 43, 46, 47. 
The in vivo results strongly confirmed the promising results obtained with the in 
vitro BBB model as, on the one hand, a decrease in particle size yielded a higher 
transcytosis rate to brain (1.6-fold increase for unmodified LNCs and 2.5-fold increase 
for CBD-decorated LNCs) and, on the other hand, the modification of LNCs with CBD 
showed higher brain targeting properties in vivo (2.5-fold increase for equally sized 
LNCs). The increase in brain levels highly correlated with the higher available plasma 
concentration and lower recognition by the reticuloendothelial organs observed for these 
formulations. As also occurred with in vitro results, it is often difficult to draw comparisons 
between in vivo results reported by different authors, especially in those studies that only 
specify the amount of fluorescent tracer distributed into the brain tissue, since this 
amount depends on the dye dose administered 48-50. A comparison with those scarce 
studies that explored the brain targeting properties of carriers within the here tested size 
range (namely, 20-60 nm) and  expressed their results as percentage of the injected 
dose per gram of brain overall revealed brain levels below those obtained herein 51, 52. In 
particular, in 51 the maximal percentage of injected dose per gram of brain tissue (slightly 
below 0.3% for the targeted nanocarrier) was accomplished at a much later time point 
(tmax around 24h) than the reported herein (0.6% of injected dose per gram of brain tissue 
at only 90 minutes following intravenous injection). However, it is worth mentioning that 
all these studies evaluated the biodistribution in glioma-bearing rodent models. Hence, 
whereas in our study only transcellular routes can be exploited for brain targeting, in the 
glioma-bearing models the transcellular routes can be significantly supplemented with 
paracellular pathways across the BBB to enhance the targeting properties (the extent of 
this contribution will highly depend on the disease stage). As a result, the evaluation of 
our nanocarrier system in an animal model of disease is expected to exhibit even higher 
values than those reported herein. Apart from that, Luo et al. had to utilize a double 
targeting strategy to achieve higher percentage of injected dose per gram of brain tumor 
52. More importantly, enhancement in brain targeting achieved with the conjugation of 
CBD to LNCs with regard to nude nanocapsules outperformed by 6-fold the 
enhancement observed for the gluthatione functionalization strategy (around 0.1% of 
injected dose per gram of brain tissue) assessed in a seminal study with healthy mice 
that laid the foundations for the G-Technology® (the main brain active strategy that has 
already entered clinical trials for the treatment of CNS diseases) 53. 
Altogether, the enhancement in the brain targeting properties of LNCs achieved 
with CBD as targeting moiety and with reduction in particle size (within the size range 
20-55 nm) has been consistently evidenced both in vitro through cellular uptake 
experiments by flow cytometry and confocal microscopy and through transport 
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experiments across an endothelial monolayer and in vivo through biodistribution studies 
in healthy mice. 
The most likely mechanism of brain targeting of CBD is receptor-mediated 
transcytosis across the brain endothelium. However, the precise mechanism remains to 
be experimentally elucidated as the procedure followed for other targeting moieties is 
not of immediate application in the case of CBD. Targeting residues are often hydrophilic 
in nature and competitive binding experiments with the free ligand can be conducted in 
vitro. This is not the case for free CBD, where competitive binding experiments would 
require the inclusion of organic solvents in the culture medium. Moreover, targeting 
ligands traditionally bind to a single receptor and through a series of experiments 
conducted in the presence and absence of competitive ligands of those receptors, the 
extent in the reduction of the targeting ability can be quantified (i.e. transferrin and 
transferrin receptor). However, CBD has been reported to interact with many different 
targets 54 and many of those could contribute to the brain active targeting mechanism to 
different extents (Table 2). 
Receptor/Ion channel Pharmacological role Ref. 
CB1 Negative allosteric modulator 22 
CB2 Negative allosteric modulator 55 
5-HT1A  Agonist 23 
TRPV receptors Agonist 56 
Glycine receptor Agonist 57 
A2A Agonist 26 
GPR55 Antagonist 25 
D2 Partial agonist 27 
Nicotinic acethylcholine 
receptor 
Allosteric inhibitor 58 
Table 2: Overview of the distinct receptors in the CNS environment to which CBD 
has been postulated to bind. CB1: cannabinoid receptor type 1, CB2: cannabinoid 
receptor type 2, 5-HT1A: serotoninergic receptor, TRPV1–2: transient potential vanilloid 
receptors, A2A: adenosine receptor, GPR55: G-protein-coupled receptor 55, D2: 
dopamine receptor. 
This fact truly hinders the experimental elucidation of the precise mechanism of 
brain active targeting of CBD because the precise quantification of the contribution to the 
BBB-targeting ability of each single receptor through inhibition of the distinct receptors 
separately is prevented, as inhibiting one receptor recognition may bias the targeting 
mechanism by upgrading alternative targeting mechanisms. Furthermore, on some of 
those receptors that CBD binds to, as it is the case of CB1, CB2 and nicotinic receptors, 
CBD acts as an allosteric ligand against which there are no current specific inhibitors 
available 22, 55, 58. 
Further research should be conducted regarding the expression of all these 
receptors/transporters at the BBB to gain insight into the potential targeting mechanism. 
So far, of the above mentioned receptors that CBD binds to, at least the nicotinic 
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acetylcholine receptor and the dopamine receptor have been evidence to be present at 
the brain endothelium 43, 59 and have started being tested as potential receptors to 
mediate brain targeting of nanomedicines with exogenous ligands 43, 60. Therefore, it is 
assumable that at least these receptors expressed on the cerebral endothelium 
contribute to the brain active targeting mechanism of CBD across the BBB. 
5. Conclusion 
We have developed and evaluated pre-clinically both in vitro and in vivo an 
innovative BBB-targeted lipid nanocarrier aimed at brain active targeting following 
intravenous administration. In particular, we obtained monodisperse LNCs by the PIT 
method and decorated them with non-psychotropic cannabinoids as pioneering brain 
targeting molecules. Both the permeability experiments across an in vitro BBB model 
and the biodistribution experiments demonstrated that the highest brain transcytosis rate 
was achieved with the smallest cannabinoid-decorated LNCs. Since the transport 
efficiency across the BBB certainly determines the efficacy of the treatments for brain 
disorders, our results indicate that small cannabinoid-decorated LNCs represent a 
promising platform for the design and development of novel therapies for CNS diseases. 
Moreover, our study serves to widen with cannabinoids the yet scarce armamentarium 
of exogenous and non-immunogenic ligands available for brain targeting. Lastly, the 
consistency between the in vitro and in vivo results served to validate our in vitro BBB 
model with the human brain endothelial cell line hCMEC/D3 as a versatile screening 
method to evaluate the passage of nanocarriers across the BBB that meets the high-
throughput demands in the early stages of drug discovery and lacks ethical constraints. 
Supporting information 
Figure on the influence of methanol addition on particle size, 3D video 
reconstructions of the Z-stack projections imaged by confocal microscopy for the distinct 
formulations tested (negative control, undecorated and targeted nanocapsules). 
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